BENEFIT 11: No new safety signals with interferon beta-1b

NEW ORLEANS – The long-term safety of interferon beta-1b for the treatment of multiple sclerosis is well established, and 11-year outcomes from the randomized, placebo-controlled BENEFIT trial...
Source: Family Practice News - Category: Primary Care Source Type: news